Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. (PEITHO-2)

• ClinicalTrials.gov Identifier: NCT02596555
• Recruitment Status: Terminated
• First Posted: November 4, 2015
• Last Update Posted: February 17, 2020
• Sponsor: Prof. Stavros Konstantinides, MD
• Collaborator: European Georges Pompidou Hospital
• Information provided by (Responsible Party): Prof. Stavros Konstantinides, MD, Johannes Gutenberg University Mainz

Study Description

Brief Summary:

This prospective, multicenter, multinational, phase IV, interventional single-armed (management) trial will focus on the safety, efficacy and cost-effectiveness of a new oral anticoagulant in the treatment of patients with acute intermediate-risk PE based on validated imaging (echocardiographic or CT angiographic) and laboratory biomarker (circulating levels of cardiac troponins and natriuretic peptides) parameters and their combinations.

Condition or disease	Intervention/treatment	Phase
Pulmonary Embolism	Drug: Dabigatran	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 400 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism
• Actual Study Start Date: January 2016
• Actual Primary Completion Date: February 2020
• Actual Study Completion Date: February 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Dabigatran treatment; Low molecular weight heparin for 72 hours followed by 6 months of dabigatran	Drug: Dabigatran; Low molecular weight heparin for 72 hours followed by 6 months of dabigatran; Other Name: Pradaxa

Outcome Measures

Primary Outcome Measures :

1. Occurrence of symptomatic venous thromboembolism (VTE) or pulmonary embolism (PE) related death (yes/no) [ Time Frame: 6 months ]

Secondary Outcome Measures :

1. Recovery of right ventricle (RV) function [ Time Frame: 6±1 days or upon discharge (whichever comes first), 6 months ]
2. Temporal pattern of changes in NT-proBNP (N-terminal prohormone of brain natriuretic peptide) levels [ Time Frame: 6±1 days or upon discharge (whichever comes first), 6 months ]
3. Death from any cause [ Time Frame: 30 days ]
4. Pulmonary embolism (PE) related death, or PE-related or hemodynamic collapse or decompensation [ Time Frame: 30 days ]
5. Overall duration of hospital stay [ Time Frame: 6 months ]
6. Major bleeding [ Time Frame: 6 months ]
7. Clinically relevant bleeding [ Time Frame: 6 months ]
8. Serious adverse events (SAE) [ Time Frame: 72 hours, 30 days, 6 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age ≥18 years
2. Objectively confirmed diagnosis of acute PE by multidetector CT angiography, ventilation/perfusion lung scan, or selective invasive pulmonary angiography, according to established diagnostic criteria, with or without symptomatic deep vein thrombosis
3. Absence of hemodynamic collapse, or decompensation, at presentation; Hemodynamic collapse or decompensation

4. Intermediate-risk category of PE severity indicated by a positive (score ≥1) simplified pulmonary embolism severity index (sPESI), in combination with the presence of at least one of the following criteria at presentation:

   • At least one sign of RV pressure overload/dysfunction on CT angiography or echocardiography
   • Signs of myocardial injury as indicated by elevated troponin levels
   • Signs of (RV) failure as indicated by NT-proBNP levels >600 pg/ml at baseline.
5. Ability of the subject to understand the character and individual consequences of the clinical trial; signed and dated informed consent of the subject available before the start of any specific trial procedures

Exclusion Criteria:

1. Pregnancy (a negative serum or urine pregnancy test should be available for women of child-bearing potential before study inclusion) or lactation
2. Women of childbearing potential who do not practice a medically accepted highly effective contraception during the trial and one month beyond
3. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
4. Participation in another clinical trial during the present clinical trial or within the last three months
5. Medical or psychological condition that would not permit completion of the trial or signing of informed consent
6. Use of a fibrinolytic agent, surgical thrombectomy, interventional (catheter-directed) thrombus aspiration or lysis, or use of a cava filter to treat the index episode of PE
7. Treatment with any therapeutically dosed anticoagulant for more than 48 hours prior to enrolment
8. Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage ≤100 mg/day;
9. Active bleeding or known significant bleeding risk (e.g., gastrointestinal ulcer, malignant neoplasms, injuries or recent surgeries of the brain, spinal cord or eyes, recent intracranial bleedings, known or suspected esophagus varices, aneurysms or intraspinal or intracranial vascular abnormalities)
10. Artificial heart valves requiring treatment with an anticoagulant
11. Renal insufficiency with estimated creatinine clearance <30 ml/min/1.73m2
12. Chronic liver disease with aminotransferase levels two times or more above the local upper limit of normal range
13. Concomitant administration of strong inhibitors of P-glycoprotein like ketoconazole, cyclosporin, itraconazole or dronedarone
14. Unwillingness or inability to adhere to treatment or to the follow-up visits
15. Life expectancy less than 6 months

Contacts and Locations

Locations

Germany

Center for Thrombosis and Hemostasis, University Medical Center Mainz

Mainz, Germany, 55131

Sponsors and Collaborators

Prof. Stavros Konstantinides, MD

European Georges Pompidou Hospital

Investigators

• Principal Investigator: Stavros Konstantinides, Prof., MD; Center for Thrombosis and Hemostasis, University Medical Center Mainz

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Klok FA, Toenges G, Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galie N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jimenez D, Kozak M, Lang IM, Lankeit M, Meneveau N, Munzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Meyer G, Konstantinides SV; PEITHO-2 investigators. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematol. 2021 Sep;8(9):e627-e636. doi: 10.1016/S2352-3026(21)00203-9. Epub 2021 Aug 4.

• Responsible Party: Prof. Stavros Konstantinides, MD, Medical Director of Center for Thrombosis and Hemostasis, University Medical Center Mainz, Johannes Gutenberg University Mainz
• ClinicalTrials.gov Identifier: NCT02596555
• Other Study ID Numbers: PEITHO-2
• First Posted: November 4, 2015
• Last Update Posted: February 17, 2020
• Last Verified: February 2020

Additional relevant MeSH terms:

Pulmonary Embolism; Embolism; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Lung Diseases; Respiratory Tract Diseases; Dabigatran; Antithrombins; Serine Proteinase Inhibitors; Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Anticoagulants